Recombinant SARS-CoV-2, Nucleocapsid (N) Protein
Cat# S854-500
Size : 500µg
Brand : Leinco Technologies
Recombinant SARSCoV2, Nucleocapsid (N) Protein
Recombinant SARSCoV2, Nucleocapsid (N) Protein
Product No.: S854
Alternate Names Nucleocapsid Protein, N Protein SARSCoV2 Product Type Recombinant Protein Expression Host HEK293 Cells Species SARSCoV2 ⋅ Virus Applications ELISA ⋅ WB |
Data
BackgroundSevere acute respiratory syndrome coronavirus 2 (SARSCoV2), the causative agent of coronavirus disease 2019 (COVID19), is an enveloped, singlestranded, positivesense RNA virus that belongs to the Coronaviridae family1. The SARSCoV2 genome, which shares 79.6% identity with SARSCoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N)2. The N protein is 46 kDa and consists of two highly conserved structural domains, the Nterminal domain (NTD) and Cterminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and selfoligomerization, respectively3,4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARSCoV N protein (8). It is also immunogenic, and antibodies8,9 and memory T cells 10,11 targeting the N protein are present in the sera of convalescent COVID19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARSCoV212. The N protein also contributes to immune evasion by antagonizing antiviral RNAi13, suggesting its potential value as a targeted therapeutic. Protein DetailsFormat Purified No Carrier Protein Purity >95% by SDS Page Product Concentration 0.5 mg/ml Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method Protein Accession No. Amino Acid Sequence MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA State of Matter Liquid Predicted Molecular Mass The predicted molecular weight of Recombinant SARSCoV2, Nucleocapsid (N) Protein is Mr 47 kDa. Predicted Molecular Mass 47 kDa Formulation This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of proteins, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Storage and Stability We recommended to store this recombinant protein as received at 28°C for up to one month. For longerterm storage, aseptically aliquot in working volumes without diluting and store at 80°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Blue Ice via Next Day Air NCBI Gene Bank Applications and Recommended Usage ? (Quality Tested by Leinco) ELISA WB References & Citations1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020. 2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020. 3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 2020 4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):5972. 2006 5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):1384813855. 2005 6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397405. 2008 7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):1027610288. 2010 8. Guo L., Ren L., et al. Diseases Society of America. 2020 9. To K.K., Tsang O.T., et al. Lancet Infect. Dis. 2020 10. Grifoni A, Weiskopf D, Ramirez SI, et al. Cell. 181(7):14891501.e15. 2020 11. Ni L, Ye F, Cheng ML, et al. Immunity.52(6):971977.e3. 2020 12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(45):206211. 2020 13. 26. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 2020 |